Study: Rosmarin 2022, New England Journal of Medicine

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

Citation

Rosmarin D, Passeron T, Pandya AG et al (2022). New England Journal of Medicine. PubMed id 36260792.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • Vitiligo Tier B moderate

    B 674 people aged 12 or over with nonsegmental vitiligo in North America and Europe (two trials); how many were Black is not in the abstract (n=674)

    Two phase 3, randomised, double-blind, vehicle-controlled trials of 1.5% ruxolitinib cream twice daily for 24 weeks.

    At week 24, 29.8% (trial 1) and 30.9% (trial 2) on ruxolitinib cream reached a 75% improvement in facial vitiligo score, against 7.4% and 11.4% on vehicle.

    As recorded in this card: Rosmarin D, Passeron T, Pandya AG et al (2022), New England Journal of Medicine, [primary]

    Note: Industry-sponsored. A prescription medicine.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.